Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Diego Cacho Lavín"'
Autor:
Ana Fernández Montes, Vicente Alonso Orduña, Elena Asensio Martínez, Nuria Rodríguez Salas, Esperanza Torres, Diego Cacho Lavín, Rosa María Rodríguez Alonso, Esther Falcó, Joan Carles Oliva, Lluis Cirera, Jesus García Gómez, Carles Pericay
Publikováno v:
The Oncologist.
Background Patients with metastatic colorectal cancer (mCRC) and KRAS mutations have a poor prognosis, seemingly dependent on the location of the mutation. This multicenter, retrospective, cohort study assessed the frequency and prognostic value of s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e1f4dbec82d3461d99778092a5e045a0
https://doi.org/10.1093/oncolo/oyad117
https://doi.org/10.1093/oncolo/oyad117
Autor:
Paula Jimenez-Fonseca, Victoria Foy, Sophie Raby, Alberto Carmona-Bayonas, Lola Macía-Rivas, Virginia Arrazubi, Diego Cacho Lavin, Raquel Hernandez San Gil, Ana Custodio, Juana María Cano, Ana Fernández Montes, Oriol Mirallas, Ismael Macias Declara, Rosario Vidal Tocino, Laura Visa, María Luisa Limón, Paola Pimentel, Nieves Martínez Lago, Tamara Sauri, Marta Martín Richard, Monserrat Mangas, Mireia Gil Raga, Aitana Calvo, Pablo Reguera, Mónica Granja, Alfonso Martín Carnicero, Carolina Hernández Pérez, Paula Cerdá, Lucía Gomez Gonzalez, Francisco Garcia Navalon, Vilma Pacheco Barcia, David Gutierrez Abad, Maribel Ruiz Martín, Jamie Weaver, Wasat Mansoor, Javier Gallego
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Trastuzumab and chemotherapy is the standard first-line treatment in human epidermal growth factor receptor 2 (HER2)-positive advanced gastro-oesophageal cancer. The objective was to develop a predictive model for overall survival (OS) an
Externí odkaz:
https://doaj.org/article/cf85aa4387664f46bdb19d331cc85d54
Autor:
Paula Jimenez-Fonseca, Alberto Carmona-Bayonas, Alba Martinez-Torron, Maria Alsina, Ana Custodio, Olbia Serra, Diego Cacho Lavin, María Luisa Limón, Tamara Sauri, Flora López, Laura Visa, Mónica Granja, Nieves Martínez Lago, Virginia Arrazubi, Rosario Vidal Tocino, Raquel Hernandez, Gema Aguado, Juana María Cano, Alfonso Martín Carnicero, Monserrat Mangas, Paola Pimentel, Ana Fernández Montes, Ismael Macias Declara, Federico Longo, Avinash Ramchandani, Marta Martín Richard, Alicia Hurtado, Aitor Azkarate, Carolina Hernández Pérez, Raquel Serrano, Javier Gallego
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Trastuzumab combined with cisplatin and fluoropyrimidines, either capecitabine or 5-fluorouracile (XP/FP), is the standard first-line treatment for advanced, HER2-positive, gastric cancer patients based on the ToGA trial. Despite the lack
Externí odkaz:
https://doaj.org/article/461c7ab35c804b44a5bffb5634234fe5